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Abstract
Background: Both naturally arising Foxp3
+ and antigen-induced Foxp3
2 regulatory T cells (Treg) play a critical role in
regulating immune responses, as well as in preventing autoimmune diseases and graft rejection. It is known that antigen-
specific Treg are more potent than polyclonal Treg in suppressing pathogenic immune responses that cause autoimmunity
and inflammation. However, difficulty in identifying and isolating a sufficient number of antigen-specific Treg has limited
their use in research to elucidate the mechanisms underlying their regulatory function and their potential role in therapy.
Methodology/Principal Findings: Using a novel class II MHC tetramer, we have isolated a population of CD4
+ Foxp3
2 T
cells specific for the autoantigen glutamic acid decarboxylase p286–300 peptide (NR286 T cells) from diabetes-resistant non-
obese resistant (NOR) mice. These Foxp3
2 NR286 T cells functioned as Treg that were able to suppress target T cell
proliferation in vitro and inhibit type 1 diabetes in animals. Unexpected results from mechanistic studies in vitro showed
that their regulatory function was dependent on not only IFN-gamma and nitric oxide, but also on cell contact with target
cells. In addition, separating NR286 Treg from target T cells in transwell assays abolished both production of NO and
suppression of target T cells, regardless of whether IFN-c was produced in cell cultures. Therefore, production of NO, not
IFN-gamma, was cell contact dependent, suggesting that NO may function downstream of IFN-gamma in mediating
regulatory function of NR286 Treg.
Conclusions/Significance: These studies identified a unique population of autoantigen-specific Foxp3
2 Treg that can exert
their regulatory function dependent on not only IFN-c and NO but also cell contact with target cells.
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Introduction
Inflammation plays a central role during the development of
autoimmune diseases. It is known that CD4
+ regulatory T cells
(Treg) are able to induce effective immune tolerance that inhibits
such inflammatory responses [1], [2], [3], [4]. Defective
development or depletion of Treg in animals, such as the naturally
arising Foxp3
+CD4
+CD25
+ Treg (nTreg), results in the develop-
ment of autoimmune diseases, including type 1 diabetes (T1D) [1],
[2], [3], [4], [5], [6], [7]. Administration of Treg, expanded in vitro,
to animals has been shown to inhibit autoimmune diseases,
including T1D [8], [9]. Previous studies have demonstrated that
different cell populations with varied phenotypes can function as
Treg, regulating both immunity and autoimmunity [10], [11],
[12], [13], [14]. Both Foxp3
+ and Foxp3
2 Treg may play a pivotal
role in the negative regulation of immune system function and
inhibition of inflammation, as well as in the prevention of
autoimmune diseases and graft rejection. Therefore, the use of
Treg as a cellular therapy to induce immune tolerance in animals
or humans may be a promising method to control inflammation
and autoimmune diseases.
In addition to the heterogeneous nTreg, whose antigen-
specificity remains largely unknown, our studies and those of
others have demonstrated that cytokine-dependent antigen-
specific Treg can be expanded following treatment with antigens
[12], [15], [16], [17], [18]. Unlike nTreg, whose function is cell-
contact dependent [1], [2], [3], [11], [19], antigen-induced
Foxp3
2 Treg may exert their function through the production
of cytokines such as IL-10 [4], [13], [14], [16], [18]. It has been
well-established that antigen-specific Treg are more potent than
polyclonal Treg in suppressing pathogenic immune responses that
cause inflammation [8], [9], [20], [21]. However, difficulty in
identifying and isolating a sufficient number of antigen-specific
Treg has limited the ability of researchers to elucidate the
mechanisms underlying their regulatory function and their
potential role in therapy. In studies to address this difficulty, we
have generated autoantigen-specific class II MHC I-Ag7 tetramers
to isolate several autoantigen-specific Treg from non-obese
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7863diabetic (NOD) as well as non-obese resistant (NOR) mice [16],
[17], [22], [23].
NOR mice are a diabetes-resistant recombinant congenic strain
of NOD mice [24], [25]. While both strains express the same
disease-associated I-Ag7 molecules, NOR mice are resistant to
T1D. Although the mechanism underlying disease resistance
remains largely unclear, it is likely that NOR mice have a
relatively more robust regulatory T cell function than their NOD
counterparts [24]. In addition, the manner in which Treg exert
their regulatory function may differ in NOR and NOD mice [17].
In order to better understand the function of autoantigen-specific
Treg from NOR mice, as well as their role in T1D development,
we have isolated NOR mouse CD4
+ T cells specific for an
immunodominant p286 (a.a. p286–300) peptide of a major
autoantigen, glutamic acid decarboxylase (GAD), involved in
T1D. We report our results from studies on these novel GAD
p286-specific T cells.
Results
GAD p286-Specific CD4
+ T Cells Isolated from NOR Mice
Produce Both IFN-c and IL-10
GAD p286-specific CD4
+ Tc e l ll i n e( N R 2 8 6Tc e l l s )w e r e
isolated from p286-immunized NOR mice, using a novel I-Ag7
tetramer (tetAg7/p286) specific for this peptide, to investigate
their function and potential role in T1D development. Our
results suggested the established NR286 T cell line was p286-
specific, as cells were positively stained by tetAg7/p286, but not
by a control tetramer (tetAg7/p206) specific for a different
GAD peptide, p206; additionally, they produced IL-2 in
response to p286, but not to p206 (Fig. 1A and 1B). In studies
to examine their response to antigen stimulation, ELISA results
showed that NR286 T cells produced IFN-c and IL-10, in a
concentration-dependent manner, but not IL-4, in response to
p286 stimulation (Fig. 2A). These results suggested that NR286
T cells may represent a novel population of T cells that are not
only Th1-like, but also have acquired a Tr1-like cytokine
secretion profile, producing both IFN-c and IL10 [4], [13],
[14].
Additional studies examined NR286 T cell phenotype, with
results demonstrating that ,98% of NR286 T cells expressed
CD25 (but not Foxp3), ,20% expressed CD40, and ,19%
expressed CD45RB (Fig. 2B). NR286 T cells did not express
CD44, CD62L, CD69, or CTLA-4 (data not shown). These results
suggested that although NR286 T cells produced IL-10, they were
different from the Foxp3-expressing nTreg.
NR286 T Cells Inhibited Diabetes Caused by NOD Mouse
Splenocytes
Because NR286 T cells produced both IFN2c and IL-10, we
examined whether they functioned as pro-inflammatory T cells or
as Treg. Adoptive transfer experiments were performed to
determine the in vivo role of NR286 T cells during diabetes
development. NR286 T cells were adoptively transferred, either
alone or with female NOD mouse splenocytes, into NOD/scid
recipient mice. NOD mouse splenocytes were also transferred
alone as controls. Recipient mice transferred with NOD mouse
splenocytes alone developed diabetes as early as at 6 wk after the
cell transfer, and all recipient mice became diabetic by 18 wk after
cell transfer (Fig. 3). In comparison, transfer of NR286 T cells
alone did not induce diabetes, suggesting they were not
diabetogenic. Interestingly, NR286 T cells not only delayed
diabetes onset by 7 wk, but also inhibited diabetes development
when they were co-transferred with NOD mouse splenocytes
(Fig. 3), as 50% of NOD/scid recipient mice that were co-
transferred with NR286 T cells and NOD mouse splenocytes
remained diabetes-free by the end of the experiment (22 wk after
the cell transfer).
In summary, these in vivo studies demonstrated that NR286 T
cells do not act like pro-inflammatory T cells that induce diabetes;
instead, they may function as Treg, with the potential to inhibit
diabetes development.
NR286 T Cells Suppressed In Vitro Proliferation of
Pathogenic BDC2.5 T Cells
In vitro experiments were then performed under eight different
culture conditions to further determine whether NR286 T cells
functioned as Treg to suppress antigen-specific proliferation of
Figure 1. Isolation and characterization of CD4
+ NR286 T cells. (A) FACS analyses of purified NR286 T cells stained with tetAg7/p286 tetramer
and an anti-CD4 antibody or tetAg7/p206 (as a negative control). The numbers shown in each quadrant represent the percentage of cells stained by
the tetramer. (B) IL-2 production by NR286 T cells (2610
5/well) in response to various concentrations of p286 or control p206 peptides plus NOR
mouse APCs (4610
5/well). Peptides were 5-fold serially diluted from 100 mg/ml. HT-2 cells were used as the indicator in a MTT assay. Data represent
average 6 SEM, n=3.
doi:10.1371/journal.pone.0007863.g001
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+ BDC2.5 T
cells in response to stimulation by p79, a highly active synthetic
peptide in stimulating the diabetogenic BDC2.5 T cells [26], was
measured with and without the presence of NR286 T cells in the
culture. The results showed that only ,11% of BDC2.5 T cells did
not proliferate beyond more than two rounds of cell division in the
presence of p79 (condition 1), compared to ,88% in the absence
of p79 (condition 2) (Fig. 4A). Our results further showed that both
non-activated (Fig. 4A, conditions 3–5) and p286-activated
NR286 T cells (conditions 6–8) were able to suppress the
proliferation of BDC2.5 T cells in response to p79. The percentage
of non-dividing CFSE-labeled CD4
+ BDC2.5 cells and cells with
less than two rounds of cell division increased from ,11% to
,55% in the presence of an equal number of non-activated
NR286 T cells (condition 3), and to ,59% in the presence of
p286-activated NR286 T cells (condition 6). In addition, the
suppression of BDC2.5 cell proliferation by NR286 T cells was
concentration-dependent, that is, proportional to the number of
NR286 T cells present in the cell culture containing BDC2.5 cells.
The data showed that, compared to the 1:1 BDC2.5:NR286 T cell
ratio, the percentage of cells with,2 rounds of cell division at
1:0.25 ratio decreased from ,55% to ,27% (condition 3 vs. 5;
without p286 to activate NR286 T cells) and from ,59% to
,35% (condition 6 vs. 8; with p286 to activate NR286 T cells)
(Fig. 4A).
Figure 2. Cytokine production and phenotype analyses of NR286 T cells. (A) Analysis of cytokine production by NR286 T cells (2610
5/well)
in response to various concentrations of p286 plus APCs. Cell culture supernatant was harvested after 24 h cell culture for ELISA (lower detection
limit, 8 pg/ml for IL-4 and 30 pg/ml for IL-10 and IFN-c). Data represent average 6 SEM, n=3. (B) Phenotypic analysis of NR286 T cells. NR286 T cells
were co-stained with anti-CD4 plus antibodies against indicated markers. Numbers in each quadrant represent the percentage of cells positively
detected by antibodies.
doi:10.1371/journal.pone.0007863.g002
Figure 3. NR286 T cells inhibit diabetes development. NOD/scid
recipient mice were transferred with either NOD mouse splenocytes
(Nspl)(1610
7 cells/mouse) alone, NR286 T cells alone (1610
7 cells/
mouse), or co-transferred with an equal numbers of both NR286 T cells
and Nspl. The difference of diabetes onset and development between
co-transferred mice and Nspl single transferred mice was significant
(p,0.002).NOD mouse splenocytes were isolated from 7–8 wk old
female NOD mice. At least 8 mice were studied in each group.
doi:10.1371/journal.pone.0007863.g003
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BDC2.5 T cell proliferation, cytokine production under the different
culture conditions was also analyzed. ELISA was used to analyze
supernatants collected from cell cultures under the various conditions
with or without p286-activation of NR286 T cells. As predicted, the
supernatant from all conditions, except BDC2.5 T cells alone,
contained a comparative amount of IFN-c (Fig. 4B). None of the
cultures produced detectable levels of IL-4. In addition, compared to
cultures containing BDC2.5 T cells activated by p79 plus antigen
presenting cells (APCs)(Fig. 4B, condition 2), the production of IL-10
was significantly reduced in the presence of either p286-activated or
non-activated NR286 T cells, especially when NR286 T cells were
present at a ratio of 1:1 or 1:0.5 (Fig. 4B, conditions 3, 4, 6 and 7).
While the reason for this reduction has not yet been identified, it
could simply have been that the IL-10 produced by BDC2.5 T cells
was suppressed by NR286 T cells. We were unexpectedly also able to
detect a significant amount of nitric oxide (NO) present in the
supernatants in all cell cultures containing NR286 T cells (Fig. 4B,
conditions 3–8). In comparison, the supernatant from cell cultures
containing BDC2.5 T cells alone, either with or without p79, did not
produce significant amounts of NO.
These results demonstrated that NR286 T cells were able to
function as Treg in vitro by suppressing the target T cell
proliferation; soluble factors other than IL-4 may be involved in
this suppressive process.
The Regulatory Function of NR286 T Cells is Dependent
on Production of Both IFN2c and NO
In order to further understand how NR286 T cells may function
as Treg, we investigated the mechanisms underlying their
suppression of BDC2.5 T cell proliferation. In particular, cytokine
or NO blockade experiments were performed under seven
different culture conditions to examine whether NR286 T cell
regulatory function was dependent upon secretion of soluble
factors detected in cell cultures (Fig. 5A). Neutralizing antibodies
against either IFN2c or IL-10, or inhibitors against NO were
added to the cell cultures to block the potential effect of these
soluble factors on BDC2.5 T cell proliferation in the presence of
NR286 T cells. The results showed that blockade of IFN-c and
NO, but not IL-10, resulted in a significant increase in BDC2.5 T
cell proliferation. In the presence of an anti-IFN2c antibody, the
percentage of CFSE-labeled CD4
+ BDC2.5 T cells with less ,2
rounds of cell division decreased from ,57% to 30% (Fig. 5A,
condition 3). In control experiments, our results showed that anti-
IFN2c blockade alone did not alter BDC2.5 T cell proliferation
(Fig. 5B, condition 2 vs. 3,). Therefore, these results excluded the
Figure 4. NR286 T cells suppress proliferation of BDC2.5 T cells. (A) Inhibition of CFSE-labeled BDC2.5 T cell proliferation co-cultured with
NR286 T cells. CD4
+ BDC2.5 T cells were isolated from BDC2.5 TCR transgenic mice and labeled with CFSE (2610
5/well), then cultured under eight
different conditions (indicated as the numbers in parenthesis shown in each histogram). In control cultures, BDC2.5 T cells were cultured alone either
(1) without p79 or (2) with p79 (0.1 mg/ml) plus CD4
+ cell-depleted irradiated APCs from NOD mice. Cells also were co-cultured in the presence of
either NR286 T cells (conditions 3–5) or with NR286 T cells plus p286 (conditions 6–8) for 4 days. NR286 T cells were added to cell cultures with a 2-
fold serial dilution starting at a 1:1 ratio (BDC2.5 T cells: NR286 T cells). The numbers shown in each histogram represent the percentage of cells that
underwent ,2 rounds of cell division. Data are representative from at least n=3. (B) Cell culture supernatant was harvested from 4-day cell cultures
under the same eight different conditions as shown in (A). Levels of IL-10 detected in conditions 3, 4, and 6–8 were significantly reduced compared to
condition 2 (p,0.01). NO production in conditions 3–8 was significantly increased compared to conditions 1 and 2.
doi:10.1371/journal.pone.0007863.g004
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BDC2.5 T cells, thereby enhancing its proliferation in the absence
of NR286 Treg. Similarly, in the presence of the active NO
inhibitor (L-NMMA), the percentage of non-dividing (or with
reduced number of cell divisions) CD4
+ BDC2.5 T cells also
decreased to ,38% (Fig. 5A, condition 6). On the other hand, the
addition of an anti-IL10 antibody or an inactive NO inhibitor
analogue (D-NMMA) to the cell cultures did not restore BDC2.5
T cell proliferation (Fig. 5A, conditions 5 and 7, respectively).
These results suggested that NR286 T cell regulatory function was
dependent on IFN2c and NO production.
Additional mechanistic studies were then performed to better
understand the relative inhibitory effects on production of
individual soluble factors (IFN2c vs. NO). Cell culture superna-
tants were collected from seven different culture conditions for
further analyses. These results showed that NR286 T cells
significantly reduced the production of IFN2c in cell culture
(Fig. 5C, conditions 2 vs. 3), while the production of NO was
increased (Fig. 5C, conditions 2 vs. 3). In the presence of an anti-
IFN-c antibody (Fig. 5C, condition 4), IFN-c was not detected in
the cell culture supernatant. Unexpectedly, NO production
(15 mM) in these cultures (Fig. 5C, condition 4) was also reduced
compared to cultures without an anti-IFN2c antibody (condition
3), which contained more than 40 mM of NO despite a reduced
amount of their IFN2c. These results suggested that blockade of
IFN2c production also suppressed NO production. In addition,
although more IFN2c was detected in cultures of p79-activated
BDC2.5 cells without NR286 T cells (Fig. 5C, condition 2) than
with NR286 T cells (condition 3), it did not lead to an increased
NO production. These results suggested that IFN2c production
alone would not induce NO production in the absence of NR286
T cells.
In contrast to the IFN2c blockade effect on NO production,
addition of the active NO inhibitor, L-NMMA, to cell cultures not
only inhibited NO production in cell cultures but also restored
IFN2c production (Fig. 5C, condition 6 vs. 3). As a negative
control, the presence of the inactive NO inhibitor, D-NMMA, did
not change the production of either IFN2c or NO (Fig. 5C,
condition 7 vs. 3). In addition, although blockade of IL-10 restored
IFN2c production, it also reduced NO production (Fig. 5C,
condition 5 vs. 3).
Altogether, these results implicated IFN-c and NO secretion as
mediators of NR286 T cell regulatory function. In addition, these
data suggested the production of IFN-c may precede that of NO
Figure 5. Blockade of IFN- -c and NO production abolished NR286 T cell regulatory function. (A) CFSE-labeled CD4
+ BDC2.5 T cells (2610
5/
well) were cultured under seven different culture conditions. In control cell cultures, BDC2.5 T cells were cultured in conditions of either (1) aloneo r
(2) with p79 plus CD4
+ cell-depleted irradiated APCs for activation. BDC2.5 T cells were also cultured with (3) an equal number of NR286 T cells. In
some experiments, antibodies against (4) IFN-c or (5) IL-10 (24 mg/ml), and NO inhibitors, either (6) L-NMMA (active) or (7) D-NMMA (inactive)
(0.2 mM), were added to the cultures to determine their effect on blocking the regulatory function of NR286 T cells. The number shown in each
histogram represents the percentage of BDC2.5 T cells that underwent ,2 rounds of cell division. Data are from at least 2 experiments. (B) CFSE-
labeled CD4
+ BDC2.5 T cells (2610
5/well) were cultured under three conditions. Similar to those in (A), in control cell cultures, BDC2.5 T cells were
cultured in conditions of either (1) alone or (2) with p79 plus CD4
+ cell-depleted irradiated APCs for activation. BDC2.5 T cells were also cultured with
(3) antibody against IFN-c (24 mg/ml), in the absence of NR286 T cells. (C) Cell culture supernatants from (A) were harvested for ELISA to detect the
presence of IFN-c, IL-10, and NO.
doi:10.1371/journal.pone.0007863.g005
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target BDC2.5 T cells.
In Vitro Regulatory Function of NR286 T Cells Is Cell-
Contact Dependent
In order to examine whether NR286 T cell regulatory function
depended solely on cytokine production, transwell assays were
performed to determine whether NR286 T cells were still able to
suppress cell proliferation without being in direct contact with the
target BDC2.5 T cells. In these assays, NR286 T cells were
cultured in the upper well and were separated from BDC2.5 T
cells (cultured in the lower well) of transwell plates. CD4
+ BDC2.5
T cells were labeled with CFSE and cultured either alone or
stimulated with p79 in the presence of CD4
+ cell-depleted APCs.
Unexpectedly, neither p286-activated nor non-activated NR286 T
cells suppressed BDC2.5 T cell proliferation (Fig. 6A, conditions 3
and 4 vs. condition 2). The addition of an anti-IFN-c antibody or
the NO inhibitor L-NMMA had no effect on either restoring or
enhancing proliferation of BDC2.5 T cells (Fig. 6A, conditions 5
and 6).
IFN-c and NO production were also assessed under the same
culture conditions. IFN-c was detected in the supernatant of cell
cultures containing BDC2.5 T cells stimulated with p79 either in
the absence or presence of NR286 T cells (Fig. 6B, conditions 2, 3,
and 4). As expected, addition of an anti-IFN-c antibody blocked
the production of IFN-c in cell cultures, and the NO active
inhibitor L-NMMA had no effect on IFN2c production (Fig. 6B,
condition 5 and 6). In comparison, no significant levels of NO
were detected in any of the conditions tested (Fig. 6B). These
results suggested that cell contact between NR286 T cells and
target cells was necessary for NO but not IFN-c production and
for suppression of BDC2.5 T cell proliferation.
Our data demonstrated that NR286 T cell regulatory function
was not only dependent on IFN-c and NO, but also on cell contact
with target cells; similarly, NO production was also dependent on
cell contact. These results provide evidence to support the
conclusion that NO may be an effector molecule downstream of
IFN2c in mediating NR286 T cell regulatory function, which is
also dependent on cell contact between NR286 T and target cells.
Discussion
We report here a novel population of Foxp3-negative GAD
p286-specific NR286 Treg isolated from NOR mice. While Th1-
like NR286 T cells secreted significant amounts of IFN-c, they
functioned as Treg. Their regulatory function was dependent not
only on IFN-c, but also on NO and cell-contact with target cells.
Similar to Foxp3-expressing CD4
+CD25
+ nTreg, NR286 Treg
expressed CD25 and were cell-contact dependent; however, they
did not express Foxp3. In addition, separating NR286 Treg cells
from target T cells abolished both NO production and suppression
of target T cells, regardless of whether IFN2c was produced in
cell cultures. These results showed that production of IFN2c
alone by antigen-activated pathogenic T cells, such as BDC2.5 T,
was insufficient to induce NO production unless Treg, such as
NR286 T cells, were also present.
Our studies did not distinguish the producers of IL-10, IFN2c
or NO in cell culture studies showing the suppression of BDC2.5 T
cell proliferation by NR286 Treg. However, our results demon-
strated that suppression of BDC2.5 T cells occurred only when
NR286 Treg were present in cell cultures. In addition, blockade of
IFN2c alone, in the presence of NR286 Treg, did not alter
BDC2.5 T cell proliferation. Even if these soluble factors produced
by activated BDC2.5 T cells contributed to the suppression of
BDC2.5 T cells, the presence of NR286 Treg was required for the
Figure 6. Inhibition of BDC2.5 T cell proliferation is cell contact dependent. (A) Transwell analyses of BDC2.5 T cell proliferation. CD4
+
BDC2.5 T cells were isolated from BDC2.5 TCR transgenic mice and labeled with CFSE (5610
5/well). BDC2.5 T cells were cultured either (1) alone or (2)
activated with p79 in the transwell lower well (L.W.). In the upper wells (U.W.), an equal number of (3) NR286 T cells alone, (4) NR286 T cells plus p286,
or NR286 T cells in the presence of either (5) anti-IFN-c or (6) the active NO inhibitor L-NMMA were cultured for 4 days. The CFSE-labeled BDC2.5 T
cells (L.W.) were harvested and cell proliferation analyzed by FACS. Data are from at least 2 experiments. (B) Cell culture supernatants obtained from
the six cell culture conditions were harvested for analysis of IFN-c and NO production.
doi:10.1371/journal.pone.0007863.g006
Antigen-Specific Foxp3
2 Treg
PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7863suppressive effect. Also, the addition of p286 peptide to the culture
medium had no effects on either the proliferation of BDC2.5 T
cells or the production of IL-10 and IFN2c, suggesting that the
regulatory function of NR286 Treg was independent of their
activation status. Our studies further showed that, in addition to
soluble factors, suppression of BDC2.5 T cells was also dependent
on cell contact between NR286 Treg and target cells; that is, the
production of these soluble factors in cell cultures, in the absence
of NR286 Treg, was insufficient to suppress BDC2.5 T cells.
The GAD p286 peptide, similar to p206 and p221 peptides, has
been demonstrated as a major immunogenic peptide in NOD
mice [27]. Our previous studies showed that GAD peptide-specific
CD4
+ T cells are able to function as Treg [16], [17]. Consistent
with our results, other studies also demonstrated that GAD-specific
CD4
+ T cells from NOD mice, or CD4
+ T cells from transgenic
mice (expressing TCRs derived from NOD mouse T cell
hybridomas specific for GAD peptides) inhibited T1D [28],[29].
In addition, our current results further demonstrated that p286-
specific T cells isolated from NOR mice, like GAD-specific T cells
from NOD mice, functioned as Treg. However, the mechanisms
underlying NR286 Treg regulatory function appeared to be
different from GAD-specific T cells isolated from NOD mice, as
they were dependent on IL-10 and independent of cell contact
with target cells [16], [18], [28], [29]. Altogether, these results
showed that, regardless of the mechanisms underlying their
regulatory function, potent diabetes-inhibitory autoantigen-specif-
ic Treg can be relatively easily induced in vivo using GAD peptides.
Because the amino acid sequences of these GAD peptides are
identical in both human and mouse, these results suggest the
possibility their use to induce potent Treg as a therapy for
treatment of T1D. This is further supported by recent phase II
clinical trials showing that GAD-treated T1D patients showed
expansion of Treg and enhanced preservation of islet cell mass
[30].
NOR mice are a class II MHC I-Ag7-bearing recombinant
congenic strain of NOD mice. However, unlike NOD mice, NOR
mice do not develop diabetes, perhaps due to having a more
robust Treg population [24], [25]. Our results suggest that the
mechanisms underlying how GAD-specific Treg cells function
may also differ between GAD-specific Treg isolated from these
two different mouse strains. NOD mouse Treg, specific for GAD
peptides, were IL-10-dependent and cell contact-independent,
while NOR mouse GAD-specific Treg were IFN-c- and NO-
dependent as well as cell-contact dependent [16], [17], [18], [23].
The reason for this difference is currently unclear. One possibility
could be due to the culture conditions used to derive NR286 T
cells. However, we consider this unlikely given that the same cell
culture protocol was previously used by us to isolate T cells specific
for different GAD peptides (p206 and p221) as well as for an
unrelated peptide (a mimetic epitope, p79, that is highly active in
stimulating BDC2.5 T cells). Isolated T cells either functioned as
Treg or as non-pathogenic cells [16], [17], [18], [23], and did not
lead to a biased production of NR286-like Treg. An alternative
possibility is that the difference in non-class II MHC genes in
NOR and NOD mice may contribute to the functional difference
between NOD and NOR mouse Treg. It is possible that non-class
II MHC background genes can influence the selection of Treg
with varied underlying regulatory mechanisms in either NOD or
NOR mice. Further studies are necessary to elucidate the potential
mechanisms responsible for the observed differences in the
regulatory mechanisms underlying different Treg in these mice.
Although NR286 T cell regulatory function was dependent on
cell-contact with target cells, their unique requirement of IFN2c
and NO for their regulatory functions and the fact that they did
not express Foxp3 distinguishes them from Foxp3-expressing
nTreg. In addition, production of NO, not IFN2c, was also
dependent on cell contact between NR286 T cells and target cells.
It is likely that a combined regulatory effect of IFN-c and NO may
be directly involved in mediating suppression of target cells and
inhibition of diabetes by NR286 Treg cells. The role of IFN2c in
the immune response is complex [31]. Its pathogenic role as a Th1
cytokine in autoimmune disease development has been well
documented [31–35]. However, IFN2c can also negatively
regulate immune responses and contribute to immune regulation
processes [31], [36], [37]. The reason why IFN-c plays these dual
roles in the immune response is unclear. It is possible that IFN-c
produced by pathogenic Th1 cells plays a pathogenic role in the
absence of NR286 Treg [38], [39]. On the other hand, in the
presence of Treg, such as NR286 T cells, IFN-c triggers NO
production, which is dependent on cell-contact between Treg and
target cells. The resulting NO may then serve as the effector
molecule that suppresses pathogenic T cells and regulates
autoimmune diseases. Alternatively, IFN-c may negatively affect
the function of pro-inflammatory Th17 cells and, together with
NO, suppress inflammatory responses [40]. Previous studies have
demonstrated that NO, which can be produced by macrophages
or dendritic cells, inhibits T cell proliferation [41], [42], [43]. It is
possible that the recruitment of autoantigen-specific Treg, such as
NR286 Treg, into an inflamed site, may facilitate the interaction
between Treg and APCs at the site, and that the production of
IFN2c and NO results in the suppression of autoimmune
responses.
In summary, the current studies have 1) identified a unique
population of autoantigen-specific Treg (NR286 T cells) from a
disease resistant strain of mice that can effectively suppress the
proliferation of pathogenic T cells and inhibit T1D, 2) demon-
strated that NR286 T cell function was dependent not only on the
production of soluble factors, including IFN2c and NO, but also
on cell contact with target cells, leading to the suppression of
pathogenic T cell proliferation and diabetes development, and 3)
provided evidence to support the hypothesis that NOR mice
contain a novel population of GAD-specific Treg that could help
prevent these mice from diabetes.
Materials and Methods
Mice
NOR mice were purchased from the Jackson Laboratory (Bar
Harbor, ME). BDC2.5 transgenic mice were a gift from Drs. D.
Mathis and C. Benoist (Joslin Diabetes Center/Harvard Medical
School, Boston, MA). All animals were housed in a specific
pathogen-free environment and were used at 7–8 wk of age.
Peptides and Immunization
GAD65 p286 (p286–300) and BDC2.5 T cell-stimulating
peptide p79 (1040–79)[23],[26] were synthesized at the Beckman
Research Institute, City of Hope and purified using reverse-phase
HPLC to a purity of .90%. Animals were immunized i.p. with
100 mg of peptide emulsified in an equal volume of incomplete
Freund’s adjuvant (IFA)(Sigma, St. Louis, MO) on days 0 and 7.
Spleens were removed from animals on day 14 for further
experiments.
Production of Class II MHC Tetramers
Production and initial use of the I-Ag7 tetramers specific for
either GAD peptides or p79 have been previously described [16],
[22], [23].
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+ T Cells and Cytokine
Assays
The procedures have been previously described [16], [17], [18].
Briefly, splenocytes isolated from p286-immunized NOR mice
were pooled and cultured in Click’s medium (Life Technologies,
Grand Island, NY) with peptide for 3 days. Cells were further
incubated in RPMI medium supplemented with 5% fetal bovine
serum and IL-2 before being separated into tetramer
+ and
tetramer
2 cells. CD4
+, tetramer
+ T cells were isolated using
FACS and magnetic beads (Miltenyi Biotech, Auburn CA).
Purified tetramer
+ cells were maintained in complete medium
(CM: RPMI medium supplemented with 5% FBS, plus IL-2). For
longer cell cultures, T cells were restimulated with peptide and
irradiated APCs (3,000 rads).
Cell staining using tetramer has been previously described [16],
[22], [23]. Briefly, T cells were stained with PE-labeled tetramer
plus the anti-TCR b chain antibody, H57, (37
oC, 1–2 h) and
analyzed by FACS using FACSCaliber (Becton-Dickinson, San
Jose, CA). All antibodies used for FACS and for in vitro inhibition
assays were purchased from eBioscience or B-D Pharmingen (San
Diego, CA).
The IL-2 bioassay has been previously described [16], [22], [23].
For ELISA, cell culture supernatant was harvested after incubating
cells with peptides for 24 h. Capture ELISA (B-D PharMingen) was
used, according to the manufacturer’s instruction, to measure the
amount of cytokines produced in the cell culture.
Adoptive Transfer of T Cells into NOD/scid Mice
For adoptive transfer experiments, NOD/scid mice received a
single i.v. injection of NR286 T cells (1610
7/mouse), NR286 T
cells plus an equal number of NOD mouse splenocytes, or NOD
mouse splenocytes alone. Recipient mice were monitored for up to
22 wk after cell transfer (when mice were 30 wk old) and were
considered diabetic after two consecutive weeks of glycosuria $2%
and blood glucose level $250 mg/dL.
Assessment of NO Levels
NO production was measured using the Greiss assay [39].
Briefly, supernatant (100 ml) from cells cultured for 24 h or 4 days
was added to 100 ml of a 1:1 mixture of 1% sulfanilamide
dihydrochloride in 5% H3PO4 buffer and 0.1% naphthylethyle-
nediamine dihydrochloride (Sigma-Aldrich). The reaction was
incubated (room temperature, 10 min) then measured at OD550
nm using an ELISA reader. Nitrate contents in the reaction were
calculated using a sodium nitrite standard curve, with a detection
threshold of 1 mM.
In Vitro Inhibition Assays Using Co-Cultures
CD4
+ T cells from BDC2.5 TCR transgenic mouse splenocytes
were purified using magnetic beads and labeled with CFSE
(carboxy-fluorescein diacetate succinimidyl ester). CD4
+ T cells
(1610
7 cells/ml) in serum-free PBS were incubated (37uC, 10 min)
with CFSE (0.8 mM), washed, and used for further analyses.
CFSE-labeled CD4
+ T cells from BDC2.5 mice (the target cells),
cultured in the absence of NR286 T cells with or without p79
(0.1 mg/ml) were used as controls. CFSE-labeled cells were also
cultured in the presence of NR286 T cells and p79, with or
without GAD p286 (15 mg/ml). Irradiated (3,000 rad) CD4
+ T
cell-depleted NOD mouse splenocytes were used as the APCs.
Cells were cultured in RPMI medium containing 5% FCS for 4
days, washed and stained with the tetAg7/p79 tetramer and an
anti-CD4 antibody to identify BDC2.5 T cells. The effect of
NR286 T cells on BDC2.5 T cell proliferation was analyzed using
FACS to determine the intensity of the CFSE in the cells and
whether the cell division was altered.
To determine the effect of different cytokines on target cell
proliferation, a saturating amount of antibodies against IL-10 or
IFN2c (24 mg/ml) was added to cell cultures of in vitro inhibition
assays; cells were incubated for 4 days before being harvested for
analyses.
To determine the effect of NO on target cell proliferation, NO
inhibitors were added to cell cultures, with procedures similar to
those described above in the in vitro inhibition assays, except that a
saturating amount (0.8 mM) of L-NMMA (an active NO inhibitor)
or D-NMMA (an inactive NO inhibitor analogue) was added to
cell culture.
Transwell Assays
NOD mouse splenocytes (5610
5 cells/well) were cultured in the
lower well of a 24-well transwell plate (Corning Inc., Corning,
NY). NR286 T cells were cultured in the upper well in the
presence of irradiated CD4
+ T cell-depleted NOD mouse APCs.
CFSE-labeled CD4
+ BDC 2.5 T cells (5610
5 cells/well) were
cultured in the lower well in the presence of irradiated APCs, with
NR286 T cells cultured in the upper well. BDC2.5 T cells were
activated with p79 (0.1 mg/ml). After 4 days, cells were washed
and stained with tetAg7/p79 and an anti-CD4 antibody.
Statistical Analyses
The Student’s t test, Wilcoxon test, and x2 test for statistical
analyses were used to calculate the statistical significance for
differences between experimental groups; p,0.05 was considered
statistically significant.
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